Skip to main content Skip to search Skip to main navigation

MDCG: Guidance on custom-made medical devices according to MDR

The Medical Device Coordination Group (MDCG) published an eight-page Q&A document titled Questions and Answers on Custom-Made Devices & considerations on Adaptable medical devices and Patient-matched medical devices (MDCG 2021-3) on 15 March 2021.

Ten pairs of questions and answers clarify how to deal with custom-made medical devices with regard to the new Medical Device Regulation (EU) 2017/745 (MDR).  

How are custom-made devices (CMDs) defined under the MDR?

  • They are specifically manufactured as prescribed by an authorized person under national law and based on their qualification.  
  • They have specific design characteristics provided by the responsible authorized person.  
  • They are intended for the exclusive use by a particular person to meet their individual conditions and needs.

Dental crowns, hand prostheses or orthoses are mentioned as examples.  

The Q&A clarifies the extent to which differences exist between custom-made, mass-produced and, for example, 3D-printed medical devices according to the new MDR. For example, manufacturers of "intermediates," which in turn are used to make or are combined with custom-made medical devices, must comply with MDR requirements.   

The MDCG is composed of representatives from all European member states, as well as a representative of the European Commission, who serves as chair. Thus, the Q&A is not a European Commission document and as such is not legally binding.


Source:

MDCG: Questions and Answers on Custom-Made Devices & considerations on Adaptable medical devices and Patient-matched medical devices

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be Interested in the Following Articles:

What is a gas?

What is a gas?

You can view the answer here:
Read more
EMA: Pilot Programme for Breakthrough Devices

EMA: Pilot Programme for Breakthrough Devices

The EMA plans to launch a pilot programme in Q2 2026 to implement the guidance for breakthrough devices issued in December 2025.

Read more
EDQM: New Ph. Eur. Chapter on Data Quality with a Focus on Digital Data

EDQM: New Ph. Eur. Chapter on Data Quality with a Focus on Digital Data

The European Pharmacopoeia (Ph. Eur.) has introduced a new general chapter that provides a framework for managing the quality of data, including digital data, throughout its life cycle.

Read more
PIC/S: Jordan FDA Joins PIC/S

PIC/S: Jordan FDA Joins PIC/S

On 1 January 2026, the Jordan Food & Drug Administration (JFDA) became the 57th PIC/S Participating Authority.

Read more
Swissmedic: Scientific GMDP Meetings

Swissmedic: Scientific GMDP Meetings

Swissmedic offers companies holding or seeking a Swissmedic manufacturing or distribution license the opportunity to discuss project-specific GMP and GDP topics in Scientific GMDP Meetings.

Read more
Purified Water – The new Chinese Pharmacopoeias and What Happens Next?

Purified Water – The new Chinese Pharmacopoeias and What Happens Next?

A new Chinese Pharmacopoeia was published in 2025. This has some significant implications for the pharmaceutical water industry, which we will discuss in more detail in this article. Firstly, it is important to note that cold WFI systems are now permitted worldwide and can be used across the board.
Read more
Previous
Next